Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives

SVEINDÓTTIR, HERDÍS; Bäckström, Torbjörn

doi:10.1080/j.1600-0412.2000.079005405.x

Cited by 88 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, we found an overall prevalence for PMDD type of 3% and that this varied between countries from 5.6% for Mexico to 1% for Hungary. Thus prevalence of this approximation for PMDD was similar to those reported using clinician assessment or daily rating scales prospectively (4,12,13). Our findings do not suggest that there was a bias to more severely affected women completing the survey.…”

Section: Discussionsupporting

confidence: 87%

The effect of premenstrual symptoms on activities of daily life

Dennerstein

Lehert

Bäckström³

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

The effect of premenstrual symptoms on activities of daily life

Dennerstein

Lehert

Bäckström³

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

“…3). As many as 75% of all women experience some sort of negative mood symptoms or physical symptoms premenstrually (Andersch et al 1986), but only 2-6% of all women actually fulfill the criteria for PMDD (Ramcharan et al 1992;Sveindottir and Bäckström 2000). Ovulation, as well as the subsequent formation of a corpus luteum, is required for the development of symptoms.…”

Section: Neuroactive Steroids Gaba a Receptors And Moodmentioning

confidence: 98%

“…However, a fraction of women (3-6%) suffer from mental and physical symptoms severe enough to require medical treatment (Sveindottir and Bäckström 2000). It can be speculated that certain women, throughout life, are more prone to respond with symptoms of depression and anxiety from hormonal changes or hormonal treatments, the earliest manifestation perhaps being adverse mood effects on oral contraceptives (Cullberg 1972).…”

Section: Neuroactive Steroids Gaba a Receptors And Mood In Postmenomentioning

confidence: 99%

“…The majority of women experience cyclical changes in one or more symptoms |related to the cyclical variations in ovarian steroids during reproductive life, most often mild physical symptoms (Sveindottir and Bäckström 2000). However, a fraction of women (3-6%) suffer from mental and physical symptoms severe enough to require medical treatment (Sveindottir and Bäckström 2000).…”

Section: Neuroactive Steroids Gaba a Receptors And Mood In Postmenomentioning

confidence: 99%

See 1 more Smart Citation

Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders

2005

Self Cite

View full text Add to dashboard Cite

Neuroactive steroids are a large group of substances having effect in the brain and on brain function. The steroids most studied are allopregnanolone (ALLO), tetrahydrodesoxycorticosterone (THDOC), pregnenolone sulfate (PS) dihydroepiandrosteronesulfate (DHEAS), and estradiol (E2). ALLO and THDOC are called gamma-aminobutyric acid (GABA) steroids as they are positive modulators of the GABAA receptor in a similar way as benzodiazepines, barbiturates, and alcohol. GABA steroids not only have similar behavioral effects as benzodiazepines and barbiturates but, possibly, also similar adverse effects as well. This review aims to elucidate the possible role that neuroactive steroids play in the development of mood disorders in women. One of the most clear-cut examples of the interaction between mood, neuroactive steroids, and the GABA system is premenstrual dysphoric disorder (PMDD), which is a cluster of negative mood symptoms occurring during the luteal phase of the menstrual cycle in 2-6% of reproductive women. Furthermore, certain women also experience adverse mood effects during sequential progestin addition to postmenopausal estrogen treatment, which is why the role of neuroactive steroids in postmenopausal women is also addressed in this review.

show abstract

“…Premenstrual symptomatology has been documented in users of oral contraceptives [5]. Clinical trials on the use of oral contraceptives for the treatment of PMS are few in numbers; the more recent findings are at best suggestive of some benefit, mostly for the physical symptoms (increased appetite, cravings, and acne) [76,77].…”

Section: Table 1 Summary Of Premenstrual Dysphoric Disorder (Pmdd) Cmentioning

confidence: 98%

Current management of premenstrual syndrome and premenstrual dysphoric disorder

Born

Steiner

2001

Curr Psychiatry Rep

View full text Add to dashboard Cite

About 5% of women of reproductive age experience affective or physical premenstrual symptoms that markedly influence work, social activities, or relationships. Prospective charting of symptoms for at least two menstrual cycles is required to facilitate an accurate diagnosis of premenstrual syndrome or premenstrual dysphoric disorder. The optimal treatment plan begins with lifestyle modifications, followed by pharmacotherapy. Evidence from numerous controlled trials has clearly demonstrated that low-dose serotonin reuptake inhibitors, using intermittent or continuous administration, have excellent efficacy with minimal side effects. Modification of the menstrual cycle should be considered only after all other treatment options have failed.

show abstract

Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives

Abstract: The normalcy of cyclicity found in this study might explain the high prevalence of premenstrual syndrome in many recall surveys. The importance of prospective daily ratings for establishing symptom cyclicity in women cannot be over emphasized.

Cited by 88 publications

References 34 publications

The effect of premenstrual symptoms on activities of daily life

The effect of premenstrual symptoms on activities of daily life

Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders

Current management of premenstrual syndrome and premenstrual dysphoric disorder

Contact Info

Product

Resources

About